At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.